resolution issues halol plant suns largest facility supplying us market help boost mumbaibased companys sales largest drug market world reuters
mumbai us drug regulator cleared sun pharmaceutical industries key plant western india reeling quality concerns two half years
move pave way nations largest drug maker launch new products halol plant gujarat state
company backed billionaire dilip shanghvi received establishment inspection report us food drug administration inspection feb 23 sun said statement tuesday fda concluded inspection closed issues contained warning letter issued december 2015 addressed said
remain committed following highest levels quality manufacturing facilities globally shanghvi said statement
resolution issues halol plant suns largest facility supplying us market help boost mumbaibased companys sales largest drug market world also give fillip suns research arm sun pharma advanced research depended halol make two key drugs treat glaucoma seizures
according motilal oswal resolution halol issue critical sun would provide visibility key approvals brokerage expects resolution help expand suns sales us 100 million
halol plant fda lens since 2014 previously accounted 25 drug makers us sales contributes barely 15 fda warning letter barred company making fresh filing drug applications unit manufactured key injectable drugs
past three half years plant received 23 observations breach quality standards multiple audits last week fda said assigned halol voluntary action indicated status suggesting plant would require reinspection
indian drug makers grappling regulatory issues amid rampant violation fda norms manufacturing standards past regular issued warning letters secondranked dr reddys laboratories thirdlargest lupin citing quality issues plants
meanwhile sun continues struggle regulatory quality control issues ranbaxys local plants since acquiring rival japans daiichi sankyo 2014 ranbaxy four plants india banned selling us
shares sun rose 1 mumbai trading benchmark sp bse sensex added 01
